ovarian adnexal mass
Aspira Q4 Revenues up 36 Percent
The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent.
Aspira Women's Health Preliminary Q4 OVA1 Sales up 23 Percent; Firm Details Pipeline Progess
The company also announced a five-year deal with healthcare group Axia Women's Health to provide in-house genetic carrier screening.
Aspira Women's Health Q3 Revenues Up 34 Percent
The cancer diagnostics firm posted $1.7 million in revenues, up from $1.2 million the year prior, and completed 4,281 OVA ovarian cancer tests.
Aspira Q2 Revenues More Than Double
The company reported total revenues of $1.8 million, up from $746,000 a year ago, and posted sales of 4,553 OVA1plus tests, up from 2,458 in Q2 2020.
The company is developing tests for ovarian mass monitoring and endometriosis that it hopes will expand its addressable market beyond that targeted by OVA1.
Nov 12, 2020
Aspira Q3 Revenues Down 8 Percent
Aug 13, 2020
Aspira Q2 Revenues Down 32 Percent
Jul 1, 2020
Aspira Eyes $11M in Private Equity Financing
May 14, 2020
Vermillion Q1 Revenues Up 55 Percent
Mar 26, 2020
Vermillion Q4 Revenues Up 42 Percent
Nov 13, 2019
Nov 12, 2019
Vermillion Q3 Revenues Up 66 Percent
May 14, 2019
Vermillion Q1 Revenues Up 24 Percent
Mar 28, 2019
Vermillion Q4 Revenues Up 16 Percent
Jan 15, 2019
Cigna Covering Vermillion's OVA1 Ovarian Cancer Test
Dec 13, 2018
Nov 8, 2018
Vermillion Q3 2018 Revenues Up 12 Percent
Jul 27, 2018
Vermillion Receives Nasdaq Delisting Warning
May 14, 2018